January 11, 2023
Automated Manufacturing Will Deliver More—and Better—Cell Therapies
Related News
-
July 21, 2026Cellares and Papillon Therapeutics Partner to Automate Manufacturing of PPL-001 for Patients With Friedreich’s Ataxia
-
July 13, 2026
Cellares and Sonoma Biotherapeutics Collaborate to Automate Manufacturing of SBT-77-7101 Engineered Treg Cell Therapy on the Cell Shuttle® Platform
-
June 30, 2026
Cellares Accepted to FDA’s Inaugural Manufacturing PreCheck Cohort, the Only Cell Therapy Platform Among Seven Companies Nationwide
